| Cai, Wei |
| Recruiting | N/A | 100 | RoW | Prebiotic fructans, Non-prebiotic maltodextrin | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH | Constipation | 12/22 | 12/22 | | |
NCT05476289: A Follow-up Study of Dragon Study (NCT03520764): to Assess the Growth and Immune-related Outcomes |
|
|
| Completed | N/A | 226 | RoW | No intervention | Danone Nutricia, Nutricia Early Life Nutrition (Shanghai) Co., Ltd | Healthy Nutrition | 11/21 | 11/23 | | |
| Recruiting | N/A | 262 | RoW | Experimental Group (EG), Control Group (CG) | Société des Produits Nestlé (SPN) | Healthy Infants | 11/26 | 06/27 | | |
| Recruiting | N/A | 326 | RoW | New infant formula with 6 HMOs blend, Standard infant formula without 6 HMOs blend | Junlebao Dairy Group Co., Ltd., Merieux NutriSciences (China) | Healthy Infants | 04/27 | 04/27 | | |
| Wang, Ying |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
| Recruiting | 1/2 | 203 | RoW | CN201, CN201 for Injection | Curon Biopharmaceutical (Shanghai) Co.,Ltd | Acute Lymphoblastic Leukemia | 05/25 | 07/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT06608329: A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 33 | RoW | HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Healthy Adult Subject | 11/24 | 12/24 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT04008524: A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies |
|
|
| Available | N/A | | RoW | CAR-T cells | Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd. | Relapsed and Refractory Hematological Malignancies | | | | |
| Recruiting | N/A | 100 | RoW | Prebiotic fructans, Non-prebiotic maltodextrin | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH | Constipation | 12/22 | 12/22 | | |
NCT04880083: Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein |
|
|
| Completed | N/A | 120 | RoW | Commercially Available Starter Infant Formula | Société des Produits Nestlé (SPN), Medrio, Inc, SAS Institute, Veeva Systems | Digestion, Gut Microbiota | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Feng, Yi |
QLG2069-AMS-301, NCT05822713: A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV. |
|
|
| Not yet recruiting | 3 | 516 | NA | Amisulpride, Amisulpride Placebo | Qilu Pharmaceutical (Hainan) Co., Ltd. | PONV | 08/23 | 12/23 | | |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Pimicotinib(ABSK021), Placebo | Abbisko Therapeutics Co, Ltd | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | 05/26 | 06/28 | | |
| Tang, Qing-ya |
| No trials found |
| Lu, Li-na |
| No trials found |
